Get to know our clinical trials
Trial of AZD8701 in combination with durvalumab in participants with advanced solid tumors.
WE ARE DOING THIS STUDY TO FIND OUT WHETHER THE DRUG CALLED AZD8701 WILL BE SAFE FOR THE TREATMENT OF DIFFERENT TYPES OF CANCERS WHEN GIVEN ALONE OR WHEN GIVEN WITH THE DRUG DURVALUMAB.
- FIRST PHASE I HUMAN STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS AND EFFICACY OF AZD8701 ADMINISTERED INTRAVENOUSLY AS MONOTHERAPY AND IN COMBINATION WITH DURVALUMAB (MEDI4736) IN PARTICIPANTS WITH ADVANCED SOLID TUMORS. IMMUNOTHERAPY
- Code EudraCT: -
- Protocol number: D9950C00001
- Promoter: Astra Zeneca AB
- Link to Clinical Trials
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.